- Research Article
Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells
Cellular & Molecular Biology Letters volume 14, pages 113–127 (2009)
Neoplastic cells frequently have an increased number of transferrin receptors. Coupling transferrin to an anti-neoplastic drug has the potential to overcome multidrug resistance (MDR). The purpose of this study was to examine the distribution and action of doxorubicin-transferrin conjugate (DOXTRF) in a leukaemia cell line (HL60), a multidrug-resistant leukaemia cell line (HL60ADR) and a normal tissue cell line (human fibroblasts). The intracellular accumulation of DOX and DOX-TRF was monitored by direct fluorescence. More DOX-TRF than free DOX was delivered to the tumour cells, and consecutively the levels of DNA double-strand breaks and apoptosis increased even in the multidrug-resistant cell line. In the normal tissue cell line, DOX-TRF did not accumulate, and therefore, the levels of DNA double-strand breaks and apoptosis did not increase. Cell viability was determined using the MTT assay. The IC50 for DOX-TRF was lower than the IC50 value for the free drug in both leukaemia cell lines. The IC50 values for the HL60 cells were 0.08 μM for DOX and 0.02 μM for DOX-TRF. The IC50 values for HL60ADR cells were 7 μM for DOX and 0.035 μM for DOX-TRF. In conclusion, DOX-TRF was able to overcome MDR in the leukaemia cell lines while having only a very limited effect on normal tissue cells.
sodium dodecyl sulfate
Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727–741.
Singal, P.K., Iliskovic, N., Li, T. and Kumar, D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 11 (1997) 931–936.
Lage, H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents 22 (2003) 188–199.
Li, H. and Qian, Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22 (2002) 225–250.
Hatano, T., Ohkawa, K. and Matsuda, M. Cytotoxic effect of the proteindoxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro. Tumour Biol. 14 (1993) 288–294.
Kratz, F., Beyer, U., Roth, T., Tarasova, N., Collery, P., Lechenault, F., Cazabat, A., Schumacher, P., Unger, C. and Falken, U. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87 (1998) 338–346.
Daniels, T.R., Delgado, T., Rodriguez, J.A., Helguera, G. and Penichet, M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121 (2006) 144–158.
Singh, M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 5 (1999) 443–451.
Wang, F., Jiang, X., Yang, D.C., Elliott, R.L. and Head, J.F. Doxorubicingallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res. 20 (2000) 799–808.
Singh, M., Atwal, H. and Micetich, R. Transferrin directed delivery of adriamycin to human cells. Anticancer Res. 18 (1998) 1423–1427.
Berczi, A., Barabas, K., Sizensky, J.A. and Faulk, W.P. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells. Arch. Biochem. Biophys. 300 (1993) 356–363.
Sun, I.L., Sun, E.E., Crane, F.L., Morre, D.J. and Faulk, W.P. Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. Biochim. Biophys. Acta 1105 (1992) 84–88.
Kobayashi, T., Ishida, T., Okada, Y., Ise, S., Harashima, H. and Kiwada, H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 329 (2007) 94–102.
Fritzer, M., Szekeres, T., Szuts, V., Jarayam, H.N. and Goldenberg, H. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrugresistant KB cells. Biochem. Pharmacol. 51 (1996) 489–493.
Gallagher, R., Collins, S., Trujillo, J., McCredie, K., Ahearn, M., Tsai, S., Metzgar, R., Aulakh, G., Ting, R., Ruscetti, F. and Gallo, R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54 (1979) 713–733.
Krishnamachary, N. and Center, M.S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer. Res. 53 (1993) 3658–3661.
Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680–685.
Wistop, A., Keller, U., Sprung, C.N., Grabenbauer, G.G., Sauer, R. and Distel, L.V. Individual radiosensitivity does not correlate with radiationinduced apoptosis in lymphoblastoid cell lines or CD3+ lymphocytes. Strahlenther. Onkol. 181 (2005) 326–335.
Lubgan, D., Distel, L., Grabenbauer, G., Jozwiak, Z. and Sauer, R. Kopplung von Doxorubicin an Transferrin ermöglicht erhöhte Wirkspiegel in multidrug-resistenten Zellen zu erreichen. Strahlenther. Onkol. 181 (2005) 95.
Lubgan, D., Distel, L., Grabenbauer, G.G. and Sauer, R. Selektive Therapie von Tumorzellen durch Kopplung von Doxorubicin an Transferrin. Strahlenther. Onkol. 180 (2004) 7.
Bryszewska, M., Piasecka, A., Zavodnik, L.B., Distel, L. and Schussler, H. Oxidative damage of Chinese hamster fibroblasts induced by t-butyl hydroperoxide and by X-rays. Biochim. Biophys. Acta 1621 (2003) 285–291.
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55–63.
Binaschi, M., Bigioni, M., Cipollone, A., Rossi, C., Goso, C., Maggi, C.A., Capranico, G. and Animati, F. Anthracyclines: selected new developments. Curr. Med. Chem. Anti-Canc. Agents 1 (2001) 113–130.
Ward, J.H., Kushner, J.P. and Kaplan, J. Transferrin receptors of human fibroblasts. Analysis of receptor properties and regulation. Biochem. J. 208 (1982) 19–26.
Gomme, P.T., McCann, K.B. and Bertolini, J. Transferrin: structure, function and potential therapeutic actions. Drug. Discov. Today 10 (2005) 267–273.
Berczi, A., Ruthner, M., Szuts, V., Fritzer, M., Schweinzer, E. and Goldenberg, H. Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur. J. Biochem. 213 (1993) 427–436.
Daniels, T.R., Delgado, T., Helguera, G. and Penichet, M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121 (2006) 159–176.
Barabas, K., Sizensky, J.A. and Faulk, W.P. Transferrin conjugates of adriamycin are cytotoxic without intercalating nuclear DNA. J. Biol. Chem. 267 (1992) 9437–9442.
Inoue, T., Cavanaugh, P.G., Steck, P.A., Brunner, N. and Nicolson, G.L. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J. Cell. Physiol. 156 (1993) 212–217.
Buchholz, T.A., Davis, D.W., McConkey, D.J., Symmans, W.F., Valero, V., Jhingran, A., Tucker, S.L., Pusztai, L., Cristofanilli, M., Esteva, F.J., Hortobagyi, G.N. and Sahin, A.A. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer. J. 9 (2003) 33–41.
Sizensky, J.A., Barabas, K. and Faulk, W.P. Characterization of the anticancer activity of transferrin-adriamycin conjugates. Am. J. Reprod. Immunol. 27 (1992) 163–166.
About this article
Cite this article
Łubgan, D., Jóźwiak, Z., Grabenbauer, G.G. et al. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells. Cell Mol Biol Lett 14, 113–127 (2009). https://doi.org/10.2478/s11658-008-0037-2
- Promyelocytic leukaemia
- DNA double-strand breaks
- Multidrug resistance